Champions OncologyCSBR -0.98%64 Gross Margin % is 46.65% as of Jan. 2026, which is 1% below its 10-year median of 47.19. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 737 Biotechnology companies, Champions Oncology ranks worse than 64.18% on this metric.
The historical rank and industry rank for Champions Oncology's Gross Margin % or its related term are showing as below:
CSBR'
s Gross Margin % Range Over the Past 10 Years
Min: 22.32 Med: 47.19 Max: 51.88
Current: 45.88
During the past 13 years, the highestGross Margin % of Champions Oncology was 51.88%. The lowest was 22.32%. And the median was 47.19%.
CSBR's Gross Margin % is ranked worse than 64.18% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs CSBR: 45.88
Champions Oncology had a gross margin of 46.65% for the quarter that ended in Jan. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Champions Oncology was -0.70% per year.
Champions Oncology (NAS:CSBR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Champions Oncology had a gross margin of 46.65% for the quarter that ended in Jan. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Champions Oncology Gross Margin % Related Terms
Champions Oncology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs ANVS, HYFT, GANX: Gross Margin % Comparison
For the Biotechnology subindustry, Champions Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Champions Oncology (CSBR) has a Gross Margin % of 46.65% as of Jan. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Champions Oncology and its competitors. This is near median its historical median of 47.19. Over the past decade, Champions Oncology's Gross Margin % has ranged from 22.32 to 51.88. According to the industry distribution chart, Champions Oncology ranks #473 out of 737 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Champions Oncology's Gross Margin % too high?
Champions Oncology's current Gross Margin % of 46.65% is near median its 10-year median of 47.19. Over the past 10 years, this metric has ranged from a low of 22.32 to a high of 51.88. The Biotechnology industry median Gross Margin % is 60.92. Champions Oncology's value of 46.65% is 23.4% below this industry median. Based on the distribution chart, Champions Oncology ranks #473 out of 737 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Gross Margin % compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #473 out of 737 companies for Gross Margin %. This places Champions Oncology in the lower half of its industry. The industry median Gross Margin % is 60.92. Champions Oncology's value of 46.65% is 23.4% below this benchmark. Historically, Champions Oncology's own Gross Margin % has ranged from 22.32 to 51.88 over the past decade. While the company's 10-year median is 47.19 vs. the industry median of 60.92, Champions Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Gross Margin % of 46.65% is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Gross Margin % is 46.65%, which is near median its own 10-year median of 47.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.14 — trading 7.3% below its estimated fair value. The current Gross Margin % is 46.65%, which is near median its 10-year median of 47.19 and 23.4% below the Biotechnology industry median of 60.92. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Gross Margin % is 46.65% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.14 is trading 7.3% below its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Gross Margin %: 46.65% (near median its 10-year median of 47.19)
GF Value™: $6.62 vs. price of $6.14 (7.3% below fair value)
Industry Position: 23.4% below the Biotechnology median (#473 of 737)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
